fluorometholone; sulfacetamide sodium - Profile

What are the generic drug sources for fluorometholone; sulfacetamide sodium and what is the scope of freedom to operate?

Fluorometholone; sulfacetamide sodium is the generic ingredient in one branded drug marketed by Allergan and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for fluorometholone; sulfacetamide sodium

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for fluorometholone; sulfacetamide sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	FML-S	fluorometholone; sulfacetamide sodium	SUSPENSION/DROPS;OPHTHALMIC	019525-001	Sep 29, 1989		DISCN	No	No

Fluorometholone and Sulfacetamide Sodium: Investment Fundamentals Analysis

Last updated: February 19, 2026

This report analyzes the investment landscape for fluorometholone and sulfacetamide sodium, focusing on their current market position, patent status, and potential for future growth. Fluorometholone, a corticosteroid, and sulfacetamide sodium, an antibiotic, are established ophthalmic agents with distinct therapeutic applications.

What is the Market Landscape for Fluorometholone?

Fluorometholone is a topical corticosteroid used to treat inflammation of the eye. Its primary mechanism of action is to inhibit the synthesis of prostaglandins, potent mediators of inflammation.

Key Applications and Formulations

Fluorometholone is available in several formulations for ophthalmic use, including:

• Suspensions: These are commonly prescribed for conditions such as uveitis, conjunctivitis, keratitis, and iritis. Examples include fluorometholone acetate ophthalmic suspension.
• Ointments: Less common than suspensions, ointments can offer prolonged contact time with the ocular surface.

Market Size and Growth Drivers

The global ophthalmic drug market is substantial, driven by an aging population, increasing prevalence of eye diseases, and advancements in treatment modalities. Within this market, topical corticosteroids like fluorometholone hold a consistent share due to their efficacy in managing inflammatory conditions.

• Prevalence of Ocular Inflammation: Conditions like allergic conjunctivitis and non-infectious anterior uveitis are common, creating a steady demand for anti-inflammatory agents.
• Generic Availability: Fluorometholone is largely off-patent, leading to widespread generic availability and competitive pricing. This ensures accessibility but also limits pricing power for manufacturers.
• R&D Focus: While fluorometholone itself is an established drug, research continues into novel drug delivery systems and combination therapies that may enhance its efficacy or patient compliance.

Competitive Landscape

The ophthalmic corticosteroid market is competitive. Fluorometholone competes with other corticosteroids such as:

• Prednisolone acetate
• Dexamethasone
• Loteprednol etabonate (a "soft steroid" with a potentially improved safety profile)

The choice of corticosteroid often depends on the specific indication, severity of inflammation, and physician preference.

What is the Patent Status of Fluorometholone?

Fluorometholone is a well-established pharmaceutical ingredient with no active, broad-coverage composition of matter patents that would prevent generic competition.

• Original Patents: The foundational patents for fluorometholone have long expired.
• Formulation and Method of Use Patents: While the active pharmaceutical ingredient (API) is generic, companies may hold patents on specific formulations (e.g., novel suspension technologies, preservative-free formulations) or specific methods of use for particular indications. These patents are typically narrower in scope and have shorter durations than composition of matter patents.
• Evergreening Strategies: Manufacturers may pursue patent extensions or new patents for minor modifications or new delivery systems to extend market exclusivity. However, these are generally not considered strong barriers to entry for generic manufacturers of the core API.

What are the Investment Fundamentals for Fluorometholone?

The investment case for fluorometholone is characterized by stability rather than high growth.

Strengths

• Established Efficacy: Decades of clinical use have confirmed its effectiveness in treating ocular inflammation.
• Broad Prescribability: It is a staple in ophthalmology for a range of inflammatory conditions.
• Cost-Effectiveness: Generic availability makes it an affordable treatment option.

Weaknesses

• Generic Competition: The absence of strong patent protection leads to intense price competition and limited pricing power.
• Slower Growth Profile: As a mature product, its market growth is largely tied to overall market expansion and demographic trends rather than novel applications or significant market share gains.
• Safety Profile Considerations: Like all corticosteroids, long-term use can be associated with side effects such as increased intraocular pressure, glaucoma, and cataracts. This can limit its use in chronic conditions where alternative treatments might be preferred.

Opportunities

• Emerging Markets: Increased access to healthcare and rising disposable incomes in developing countries can drive demand for established, affordable ophthalmic treatments.
• Combination Products: Development of fixed-dose combinations with other ophthalmic agents (e.g., antibiotics or mydriatics) could create new product offerings and extend exclusivity for specific formulations.
• Advancements in Delivery Systems: Innovations in drug delivery (e.g., sustained-release formulations) could improve patient compliance and potentially offer a differentiated product.

Threats

• Competition from Newer Steroids: Development of corticosteroids with improved safety profiles (e.g., loteprednol etabonate) may erode market share.
• Development of Non-Steroidal Anti-Inflammatories: Advances in non-steroidal treatments for ocular inflammation could reduce reliance on corticosteroids.
• Regulatory Scrutiny: Increased focus on drug safety and potential side effects of long-term corticosteroid use.

What is the Market Landscape for Sulfacetamide Sodium?

Sulfacetamide sodium is a sulfonamide antibiotic used topically to treat bacterial infections of the eye. It functions by inhibiting the synthesis of folic acid, which is essential for bacterial growth.

Key Applications and Formulations

Sulfacetamide sodium is primarily used for:

• Bacterial Conjunctivitis: Commonly known as "pink eye," this is a frequent indication for sulfacetamide sodium.
• Blepharitis: Inflammation of the eyelids.
• Other Superficial Ocular Infections: It is effective against a range of common ocular pathogens.

It is available in both ophthalmic solutions and ointments.

Market Size and Growth Drivers

The market for ophthalmic antibiotics is driven by the incidence of bacterial eye infections. While generally stable, this market can be influenced by:

• Hygiene Practices: Public health initiatives and awareness campaigns around eye hygiene can impact the incidence of infections.
• Antibiotic Resistance: The growing concern of antibiotic resistance could influence prescribing patterns and the demand for older, broad-spectrum antibiotics.
• Availability of Alternatives: The development of newer antibiotic classes or non-antibiotic treatments for specific ocular conditions could affect market share.

Competitive Landscape

Sulfacetamide sodium competes with a range of other ophthalmic antibiotics, including:

• Fluoroquinolones (e.g., moxifloxacin, levofloxacin)
• Aminoglycosides (e.g., gentamicin, tobramycin)
• Macrolides (e.g., azithromycin)

Newer agents often offer broader spectrum coverage, lower minimum inhibitory concentrations (MICs) against certain pathogens, or different dosing frequencies, posing competitive challenges.

What is the Patent Status of Sulfacetamide Sodium?

Similar to fluorometholone, sulfacetamide sodium is a legacy drug with expired foundational patents.

• Expired Composition of Matter Patents: The original patents covering sulfacetamide sodium have long since expired.
• Generic Status: It is widely available as a generic medication.
• Potential for Formulation Patents: As with fluorometholone, companies might hold patents on specific formulations, such as preservative-free versions or novel delivery systems, but these do not protect the active ingredient itself.

What are the Investment Fundamentals for Sulfacetamide Sodium?

The investment fundamentals for sulfacetamide sodium mirror those of fluorometholone in many respects, pointing to a mature market with limited growth potential driven by cost and accessibility.

Strengths

• Proven Efficacy Against Common Pathogens: It is effective against many of the bacteria that cause common ocular infections.
• Long History of Use: It has a well-established safety and efficacy profile based on decades of clinical experience.
• Low Cost: Its generic status makes it a highly affordable option, particularly important in resource-limited settings.

Weaknesses

• Limited Spectrum of Activity: Compared to newer broad-spectrum antibiotics, sulfacetamide sodium's spectrum can be narrower, and resistance can be a concern.
• Risk of Resistance: Widespread use of sulfonamides has contributed to the development of bacterial resistance, potentially limiting its effectiveness over time.
• Allergic Reactions: Sulfonamides can cause allergic reactions in a subset of the population.
• Generic Price Erosion: Intense competition among generic manufacturers drives prices down significantly.

Opportunities

• Combination Therapies: Potential for combination with other ophthalmic agents for synergistic effects or broader coverage.
• Emerging Markets: Continued demand in developing countries due to its affordability and effectiveness for common infections.
• Niche Applications: Potential for continued use in specific indications where it remains a preferred agent or where cost is a primary consideration.

Threats

• Emergence of Antibiotic Resistance: This is the most significant threat, as it directly impacts the drug's clinical utility.
• Competition from Newer Antibiotics: Advanced antibiotics with broader spectra, better penetration, or improved resistance profiles can displace older agents.
• Shifting Treatment Paradigms: Increased emphasis on judicious antibiotic use and the exploration of non-antibiotic approaches to managing ocular infections.
• Regulatory Actions: Potential for increased scrutiny on antibiotic stewardship and the use of older agents, especially if resistance concerns escalate.

Comparative Analysis: Fluorometholone vs. Sulfacetamide Sodium

Both fluorometholone and sulfacetamide sodium represent mature pharmaceutical products with established efficacy and generic availability.

Feature	Fluorometholone	Sulfacetamide Sodium
Therapeutic Class	Corticosteroid (Anti-inflammatory)	Sulfonamide Antibiotic (Anti-infective)
Primary Use	Ocular inflammation (uveitis, conjunctivitis, etc.)	Bacterial ocular infections (conjunctivitis, etc.)
Patent Status	Expired (API), potential for formulation patents	Expired (API), potential for formulation patents
Market Position	Established, stable, mature	Established, stable, mature
Key Growth Drivers	Aging population, prevalence of eye disease	Incidence of bacterial eye infections
Competitive Risk	Newer steroids, non-steroidal anti-inflammatories	Newer antibiotics, antibiotic resistance
Key Investment Driver	Market stability, cost-effectiveness	Market stability, cost-effectiveness, accessibility
Major Threat	Steroid side effects, newer agents	Antibiotic resistance, newer agents
Pricing Power	Low (due to generic competition)	Low (due to generic competition)

Investment Outlook

The investment outlook for both fluorometholone and sulfacetamide sodium is characterized by a low-risk, low-growth profile. Companies involved in the manufacturing and distribution of these APIs and their finished dosage forms are likely to see stable, albeit modest, revenue streams.

• Generic Manufacturers: Companies with efficient manufacturing processes and established distribution networks for generic ophthalmic drugs are best positioned to capitalize on these products. Profitability will depend on volume and cost control, given the price-sensitive nature of the market.
• Specialty Pharma: Companies holding patents on novel formulations or combination products involving these APIs could achieve temporary market exclusivity and higher margins for those specific products, but the underlying API remains generic.
• R&D Investment: Significant investment in research and development for the base APIs is unlikely to yield substantial returns due to their mature status and patent expiries. Focus would be on formulation enhancements or identifying new niche applications.

Key Takeaways

• Fluorometholone and sulfacetamide sodium are mature ophthalmic agents with expired composition of matter patents, leading to widespread generic availability and intense price competition.
• Their market stability is driven by established efficacy, broad therapeutic use, and cost-effectiveness, particularly in managing ocular inflammation and bacterial infections, respectively.
• Investment opportunities lie primarily with generic manufacturers focused on efficient production and distribution, or specialty firms developing innovative formulations or combination products for temporary market differentiation.
• Key investment risks include ongoing price erosion due to generic competition, the emergence of antibiotic resistance for sulfacetamide sodium, and the development of newer therapeutic agents with improved safety or efficacy profiles for both drugs.
• Future growth is expected to be modest, largely tied to demographic trends and the overall expansion of the ophthalmic market, rather than significant new market penetration or therapeutic breakthroughs for the base APIs.

Frequently Asked Questions

1. Are there any remaining patents that could offer exclusivity for fluorometholone or sulfacetamide sodium? While the patents covering the active pharmaceutical ingredients (APIs) themselves have long expired, companies may hold patents on specific novel formulations, delivery systems, or methods of use. These patents are typically narrower and shorter-lived than composition of matter patents.

2. What is the primary factor limiting revenue growth for these drugs? The primary limiting factor is their status as generic drugs. Intense price competition among manufacturers of the active pharmaceutical ingredient and finished dosage forms significantly constrains pricing power and revenue growth.

3. What is the major threat to the continued market relevance of sulfacetamide sodium? The most significant threat to sulfacetamide sodium is the increasing prevalence of antibiotic resistance in bacteria. As resistance grows, the drug's effectiveness diminishes, potentially leading physicians to opt for alternative antibiotics.

4. How do fluorometholone and sulfacetamide sodium compare in terms of investment risk and reward? Both drugs present a low-risk, low-reward investment profile. They offer stable revenue streams but limited potential for substantial capital appreciation due to market maturity and generic competition. Risks are moderate, primarily centered on competitive pressures and evolving therapeutic landscapes.

5. Can companies innovate with fluorometholone or sulfacetamide sodium to create new investment opportunities? Innovation can occur through developing new formulations (e.g., sustained-release, preservative-free), creating fixed-dose combination products, or identifying novel niche indications. These strategies may provide temporary market exclusivity and differentiated product offerings, thus creating limited new investment opportunities.

Citations

[1] American Academy of Ophthalmology. (n.d.). Corticosteroids. Retrieved from https://www.aao.org/eye-health/drugs/corticosteroids

[2] U.S. Food and Drug Administration. (n.d.). Drug Approval Packages. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/drug-approval-packages

[3] World Health Organization. (2023). Antibiotic resistance. Retrieved from https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance